Table 2.
Schedule of events for the Conectad@s Project.
|
|
RDSa/ Baseline |
Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Early Terminationb | HIV seroconversion visit | Unscheduled visit | ||||||||||
| Questionnaires | |||||||||||||||||||
|
|
Behavioral, partnership, network, and structural measures | X | X | X | X | X | X | X | —c | — | |||||||||
|
|
Technology-based intervention: inclusion | X | — | — | — | — | — | — | — | — | |||||||||
|
|
Technology-based intervention: acceptability | — | — | — | X | — | — | — | — | — | |||||||||
| Laboratory procedures | |||||||||||||||||||
|
|
HIV antigen rapid test | X | Xd | Xd | Xd | Xd | Xd | Xd | X | Xe | |||||||||
|
|
HIV RNAPool | Xf | Xf | Xf | Xf | Xf | Xf | Xf |
|
Xf | |||||||||
|
|
HIV RNA viral load | Xg | Xh | Xh | Xg | Xh | Xg | Xg | X | Xe | |||||||||
|
|
CD4/CD8 | Xi | Xj | Xj | Xi | Xj | Xi | Xi | X | Xe | |||||||||
|
|
HIV recency testing | Xi | — | — | — | — | — | — | — | Xe | |||||||||
|
|
HIV genotyping | Xk | Xl | — | — | — | — | — | X | Xe | |||||||||
|
|
Urine (CTm/NGn) | X | — | — | X | — | X | X | X | — | |||||||||
|
|
Oropharyngeal swab (CT/NG) | X | — | — | X | — | X | X | X | — | |||||||||
|
|
Anal swab (CT/NG) | X | — | — | X | — | X | X | X | — | |||||||||
|
|
Anal swab (HPVo) | X | — | — | — | — | — | — | — | — | |||||||||
|
|
Anal cytology | X | — | — | — | — | — | — | — | — | |||||||||
|
|
Hepatitis B rapid test | X | — | — | — | — | Xp | Xp | Xp | Xe | |||||||||
|
|
Hepatitis B serology | Xq | — | — | — | — | Xq | Xq | Xq | Xe | |||||||||
|
|
Hepatitis C rapid test | X | — | — | — | — | Xr | Xr | Xr | Xe | |||||||||
|
|
Anti-HCV | Xs | — | — | — | — | Xs | Xs | Xs | Xe | |||||||||
|
|
RNA Hepatitis C viral load | Xt | — | — | — | — | Xt | Xt | Xt | Xe | |||||||||
|
|
Treponemal syphilis rapid test | X | — | X | X | X | X | X | X | Xe | |||||||||
|
|
Non-treponemal syphilis testing (VDRL) | Xu | — | Xu | Xu | Xu | Xu | Xu | Xu | Xe | |||||||||
|
|
DBSv (PrEP adherence assessment) | Xw | Xw | Xw | Xw | Xw | Xw | Xw | Xw | Xe | |||||||||
|
|
Creatinine | Xx | Xf | Xf | Xx | Xf | Xx | Xx | Xf | Xe | |||||||||
|
|
Complete blood count | Xf | Xf | Xf | Xf | Xf | Xf | Xf | Xf | Xf | |||||||||
aRDS: respondent-driven sampling.
bWithdrawn or discontinued participants before the final visit.
cNot applicable
dOnly for HIV-negative participants in a prior visit.
eIf necessary.
fOnly for postexposure prophylaxis use.
gOnly for HIV-positive participants or HIV-negative participants with recent HIV exposition according to INI-Fiocruz guidelines (HIV acute infection screening).
hOnly for HIV-negative participants with recent HIV exposition according to INI-Fiocruz guidelines (HIV acute infection screening).
iOnly to HIV-positive participants or to participants with HIV rapid test, HIV RNA Pool or HIV RNA viral load positive result.
jOnly to participants with HIV rapid test, HIV RNA Pool or HIV RNA viral load positive result, with negative HIV rapid test in a prior visit.
kOnly HIV-positive participants ART naïve
lOnly HIV-positive participants with prior ART use (before study initiation).
mCT: Chlamydia trachomatis.
nNG: Neisseria gonorrhea.
oHPV: human papilloma virus.
pOnly for negative Hepatitis B rapid test at baseline.
qOnly for positive Hepatitis B rapid test.
rOnly for negative Hepatitis C rapid test at baseline.
sOnly for positive Hepatitis C rapid test.
tOnly for positive anti-HCV.
uOnly treponemal syphilis rapid test.
vDBS: Dried blood spot.
wOnly for participants using PrEP.
xOnly for participants using PrEP or PEP.